INTRODUCTION
Statins are widely used in the treatment of hyperlipidaemia.
Common side effects associated with statin therapy include headache, gastrointestinal symptoms and musculoskeletal complaints. These are usually mild, transient and nonspecific.
However, statins have the potential to cause myopathy and rhabdomyolysis, which may be induced by a complex interaction among drugs, diseases and genetics. While the mechanism is not completely understood, the clinical association appears to be dose-dependent and higher with specific drug interactions. Although rhabdomyolysis is rare, it is important to note that a significant proportion of patients on statin therapy do experience musculoskeletal complaints. Although there are no fixed terminologies used to describe muscle toxicity, the American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute (ACC/AHA/NHLBI) Clinical Advisory (1) has summarised the definitions of muscle symptoms, as shown in Table I . 
INTER ACTIONS OF CY TOCHROME P4 5 0 INHIBITORS AND INDUCERS WITH STATINS
Fluvastatin and rosuvastatin, metabolised by a different CYP2C9 isoenzyme, are thought to be less subject to these interactions. Nevertheless, some patients taking fluvastatin have been reported to have an increased incidence of transaminitis and musculoskeletal effects when the drug was coadministered with cyclosporine.
(1) Caution should also be exercised when these statins are used with warfarin and protease inhibitors. (3, 4) 
Fibrates and statins
Statins with fibrates deserve particular attention because myopathy can occur with either drug alone, and they may be additive when used together. A review of 36 published clinical trials involving the statin-fibrate combination therapy found that the prevalence of myopathy was 0.12%. (3) In particular, the risk of developing of myopathy is mainly described with gemfibrozil and not fenofibrate. Gemfibrozil competitively inhibits CYP2C8
and also inhibits glucuronidation of statins, whereas fenofibrate is an inducer of both CYP3A4 and CYP2C8. This difference may explain the relative safety of fenofibrate versus gemfibrozil when used together with statins. The statin-gemfibrozil combination is contraindicated, while combination with fenofibrate may be considered for refractory or mixed hyperlipidaemia with severe hypertriglyceridaemia, especially in the presence of high cardiovascular risks.
Genetic differences
The 
HOW DO STATINS DAMAGE MUSCLE?
The mechanism of statin-induced myopathy is unknown, 
SAFE T Y OF STATINS IN SING APORE
There are six different types of statins licensed in Singapore, namely simvastatin, atorvastatin, lovastatin, pravastatin, fluvastatin and rosuvastatin. As mentioned earlier, the risk of statin-induced myopathy or rhabdomyolysis could be due to drug interactions in the CYP450 system. This risk is also dose-dependent. Table II . There are also recent reports regarding uncommon cognitive side effects, increased blood glucose and glycosylated haemoglobin with the use of statins.
APPROACHES TO STATIN USE IN PATIENTS WITH R AISED CK OR M YALGIAS
The safety and cardiovascular benefits of statins support their use as first-line treatment for hyperlipidaemia. However, there should be appropriate awareness of and attention to the potential for myopathy or rhabdomyolysis with statin therapy, as well as their interactions with other drugs. (Table II) . Usually, after the aforementioned conditions are ruled out, the patient's cardiovascular risk profile, lipid goals, severity of muscle symptoms and degree of CK elevation should influence clinical decision-making. (8) Some suggested approaches are as follows:
1. In asymptomatic patients with CK level not more than three times the upper limit of normal (ULN), a low dose of a statin may be considered in order to reach cholesterol level goals. Testing of CK level in these patients should be repeated within two weeks of initiation of statin treatment.
If the CK level is not rising, it should be checked again in 2. In patients whose CK levels are more than ten times the ULN and/or have myoglobinuria or raised creatinine levels, the prescribed statins should be stopped immediately and elevated CK should be urgently managed so as to reduce the risk of secondary renal injury.
3. In those with moderate to severe myalgia while on statin, the statin treatment should be stopped regardless of CK level.
4. In patients who have mild to moderately elevated CK levels not exceeding five times the ULN and in those whose statin has been discontinued or reduced due to inability to tolerate higher doses, the following options may be considered to help achieve target levels of LDL cholesterol and non-highdensity lipoprotein cholesterol levels: (a) addition of ezetimibe and/or bile acid sequestrants (BAS), e.g. cholestyramine, to a statin dose that is tolerated by the patient. The expected additional LDL-lowering for ezetimibe is 15%-20%, and up to 30% for the maximum dose of cholestyramine. 
TA KE H O M E M E S SAG E S
1. Statins are commonly used in our community for the treatment of hyperlipidaemia. 
